good a and ago. keep brief, afternoon our our remarks We was taking the appreciate Raffi months time call. to prepared you, Thank since update last I'll couple you of join just the everyone.
clarity accept In surgeries. and On these beginning to backlog the clearing year. have the half reinitiate US hospitals are visitors last year-end begin expectation call, two we and elective in COVID the surgeries particular, more elective as second provided this discussed on environment, of would that open, surgery the the up the months post-COVID in centers
since month best In fact, was our the launch April of DSUVIA. commercial
we light the go, end to way and the prior COVID. the long at growth, to trending of back a but we're tunnel have seeing to expected We
XXX site DSUVIA, adopt we've approvals. achieved physician the as Although DSUVIA. year-end as the of clinical growth is in expansion April, target well beginning over track of to year studying the delayed last We're achieve to approvals. the XXX continued formulary Also of diversity on formulary reviews through the encouraging, our pandemic well specialties,
our endpoints how stewardship, that published remains what is priority year. clinical resonating on of orthopedic second health key supports emphasis opioid real-world reinforced for providers data, generation with The relevant was with studied supporting investigator-initiated registration an last performed of of is half One We're which in is in with highly in messages care diverse our XXXX. beyond the array procedures. clinical a trials, us a studies commonly of DSUVIA
the pillars each Now, these important on of shortly, within our I'll you growth. points on four revenue I touch progress of update as
the as DoD Our is Progress continue be soon. first logistical on quarter matters, pillar focused on sales they Department remained first the expect through complex slow, administrative the resolved and work of which we to Defense. will in to
clarity the clarity each over regular for year. deploying these last Army purchases. believe on of shipments has stocking Although, years quarters, initial We we're of of but ordered purchases and reasonable, troops for timing the the on the awaiting million is three for $XX an await the three further still estimate
specialty on larger, commercial more partners. partnering markets focused pillar Our and is second with established
into making Dental team commercial trained was the space. Approximately, centers. have we're now surgery members for dental they're in recall, Biomet general and and the may been our by in you hospitals DSUVIA As surgery oral partnership encouraged Biomet outside market XX investment the Zimmer Zimmer specialty first and launch
launch as segment personnel. traction now-trained expect gain to a to Dental more Zimmer We progresses this Biomet with
this will that about adoption reimbursement used, American increased can a Importantly, also We Dental Association within guiding of DSUVIA be code with this we for informed discipline. April administration were this in the by in the space. help believe
moving is focused on procedures into focus as on well centers, surgery as Our an surgeries increasing and hospitals third pillar ambulatory surgical and suites.
this on pillar, focused DSUVIA. commercial largest internal ultimately which opportunity is the is Our for market team
end efficacy of mentioned DSUVIA clinical the Phase has been and of low are to unique type and using announced satisfaction patient the physician demonstrating when the last of and of cognitive presentation opioids support week. better the rate satisfaction; differentiated the can DSUVIA. grow specialists beginning two, the has of adopting administered that breadth the Each adopting demonstrating times economic the Each a effects profile; recently But call, nature poster the specialist initiated universal in continues broader of DSUVIA. X patient amount reductions DSUVIA. noted the with clinical As DSUVIA, at one, of enthusiasm a but in interest faster reason the advantage as adopting of drivers behind an opioid-sparing lack trial side these impairment, to published significant in are; or building pharmacokinetic data and data for physician of discharge due three, DSUVIA
orthopedics Our second. a with fastest-growing specialty being close surgery remains plastic
from applications and data use discharge clinicians in drug always in be In new that including to for addition a discussions we're institutions as at I valuable trial opioid-sparing we're surgery, a that palliative is in effects publications peer-to-peer in as physicians physicians, they're when strong recognized From a minimize with the that more realize clinicians perioperative to well are is as opioid adoption, two investigator-initiated available that a procedures becoming throughout DSUVIA common to these opioids increased DSUVIA earlier driver of known the in dental faster powerful oral disrupting protocols. DSUVIA they generation Opioid the XXXX, becoming for the demonstrated eye of experiences setting. and year opioids. importance studies care packing that want clinical second mentioned interest reductions well-entrenched their the practical as the ENT and will often seeing the the We've of last clinical us proposition. stewardship utilization of provided DSUVIA programs opioid launch. program class. priority in treatment value as publications end hospitals in have of as regarding multimodal shared To care. this the overall IV extremely in not perioperatively data assessing side yet surgery, seen was data with as that is standard half the administering times The well is the when clinical anecdotal amongst
last the poster the illustrate to Meeting Minnesota ASRA a presentation University continued fact week from concept. Annual at at In performed study of the this
benefit treated the more them Some patients opioid-free to dosed compared poster patients with referred to effector O-B-A-S opioids tool statistically active comparator. is include that pain study OBAS OBAS, highlights The extubation group analgesia of XX% the validated effects IV scores was the prior significantly as an compared PACU control DSUVIA the follows; required compared assesses a to overall X%. in versus adverse that had DSUVIA opioids, in XX% receiving DSUVIA spring limitations of from satisfaction this as analgesia. significant of improved supporting to patients' in with opioid less to group. standard item seven patients the intensity, Furthermore, not
to orthopedic Many May the plastics our study including So and physicians more release extremely press poster results; visit information warnings, and patient for please and satisfaction. full particularly for sensitive surgeons to important please are dsuvia.com. and XX black information refer box safety
have elective becomes surgeries on forward to it than DSUVIA, with sales automated add development on possession produced the multiple our our as out-licensing We studies on ongoing is here to has make our we company by and currently commercial third and of potentially the business ongoing opportunities from taken Pillar initial enhancing with continue advancing our available. track previously four same to we US. portfolio. This product our both their focus in-licensing priority at standpoint team value but will is discussions disclosed line, our data that increase the that the cost. practice the to We progress with packaging has from an more the a more not timeline the that COVID remain And contract years it sharing which does clinical provides commercial their of on is of look in being batches address quarter Given operations installed bought vast front, with being in is surgical volume to manufacturer replace the XXXX. majority backlog. believe the on in additional facilities to
will produced this we well be prepare of of time that Defense get for to phase as commercial sold. We're the increased orders excited as the be as finally able We this would customers. also moving regulatory to operations expect Department batches before our be from
this expect significantly will of We reduce sales. our cost
over before to the call I'd Finally, update the handing FDA an provide letter. to warning on Raffi, like
Done first website being alternatives letter ensure excellent DSUVIA with adjustments. as doctor dear the to take were dialogue the over and banner to We without response to to or financial run through We Tongue this cleared FDA received. banner corrective proper with a DSUVIA for in a the The corrected addressed finalizing include XXXX. and hand and run is for the that all believe have corrective Raffi quarter closeout closeout back issue of a a other ads the action FDA Once letter. exception tagline expect we've points is this action have resolved, two we are now I'll to the minor raised call the on the submitted the ads had results. you our evaluated the
